Ignite Creation Date:
2025-12-24 @ 11:53 AM
Ignite Modification Date:
2025-12-28 @ 2:49 PM
Study NCT ID:
NCT02961361
Status:
COMPLETED
Last Update Posted:
2023-02-15
First Post:
2016-10-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
the Effect of Dexmedetomidine in Coracoid Approach Brachial Plexus Block
Sponsor:
The First Hospital of Qinhuangdao
Organization:
Study Overview
Official Title:
the Effect of Dexmedetomidine in Coracoid Approach Brachial Plexus Block
Status:
COMPLETED
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Dexmedetomidine is an α-2 adrenoreceptor agonist and has been extensively used through intravenous infusion，in order to improved the quality of block in regional anesthesia. In this prospective, randomized study, the authors focus on the effect of dexmedetomidine mixed with ropivacaine in coracoid approach brachial plexus block.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: